There remains poor characterization of any differences in impact to atopic dermatitis (AD) based on the area affected. To estimate the prevalence and health-related quality of life impact of head/face/neck/hand involvement among patients with moderate-to-severe AD, all TARGET-DERM AD registry patients with moderate/severe Investigator Global Assessment were assessed using the Patient Oriented SCORing Atopic Dermatitis, Patient Oriented Eczema Measure and the (Children’s) Dermatology Life Quality Index.
Read more at the Journal of the American Academy of Dermatology.
Leave a Reply